Quebec City, January 27, 2009—A research team including Serge Rivest of University Laval's Faculty of Medicine has demonstrated the existence of a type of cells that limits brain damage after a stroke. The study was recently published in the online version of Nature Medicine.
Laboratory experiments showed that three days after a stroke, the affected area of the brain is 20% larger in mice without regulatory T (Treg) cells than in normal mice. Effects on locomotor control are also more severe in mice lacking this type of cells.
"These results lead us to believe that we could better preserve crucial functions like sight, speech, or control of the limbs if we rapidly stimulated the production of Treg cells in stroke victims," commented Professor Rivest. "We are particularly enthusiastic about this discovery because we already know what chemicals stimulate the production of Treg cells," continued the researcher. "So a treatment may be available in the not too distant future. We also believe that the protective effect of Treg cells could be used to treat other types of brain damage, especially that caused by head injury."
Part of the brain damage occurring after a stroke is caused by the body's immune response. Cells such as microglia and lymphocytes provoke harmful effects similar to those observed during nervous system infections. When performing their cleaning functions, these cells also attack healthy cells, enlarging the damaged area of the brain and threatening certain brain functions. Researchers had suspected the existence of a mechanism that slows this harmful effect of immune cells in the brain, but no one had yet been able to demonstrate it.
Treg cells, produced in the bone marrow and other organs of the immune system, migrate to the brain during the first few days after a stroke. They limit the extent of secondary damage by blocking the production of neurotoxins and modulating the action of lymphocytes and microglia in the brain.
The following researchers coauthored this study with Serge Rivest: A. Liesz, E. Suri-Payer, C. Veltkamp, T. Giese, and R. Veltkamp from the University of Heidelberg; H. Doerr and C. Sommer from the University of Mainz.
Information:
Serge Rivest
Faculty of Medicine
University Laval
Tel.: 418-656-4141, ext. 46236
serge.rivest@crchul.ulaval.ca
Journal
Nature Medicine